HeartBeam Receives Buy Rating Upgrade Following FDA Clearance for Cardiac Technology
HeartBeam Inc. (NASDAQ: BEAT) has been upgraded from Hold to Buy by Joseph Gunnar & Co., with the firm raising its 12-month price target to $4 from $1, according to a recent report. The upgrade reflects what the report describes as a significant turning point for the company following regulatory progress. This shift is primarily attributed to the U.S. Food and Drug Administration’s clearance of HeartBeam’s 12-lead ECG synthesis software in December 2025 for arrhythmia assessment. The clearance resolved an earlier regulatory setback and allowed the company to transition toward commercial-stage status.
The company’s core technology focuses on transforming cardiac care by enabling powerful cardiac insights outside traditional medical facilities. HeartBeam is developing what it calls the first-ever cable-free 12-lead ECG system capable of capturing the heart’s electrical signals in three dimensions. This platform technology is designed for use in portable devices, allowing physicians to identify cardiac health trends and acute conditions remotely and direct patients to appropriate care. The company holds 13 U.S. and 4 international-issued patents related to this technology. For more information on the company’s technology and mission, visit https://www.HeartBeam.com.
The investment firm’s February 2026 report explicitly linked the upgrade to progress in cardiac risk detection, stating, ‘We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection.’ The regulatory milestone is seen as enabling HeartBeam’s shift from development to commercialization, potentially redefining aspects of cardiac health management by moving diagnosis and monitoring out of clinical settings. This development is significant for the medical technology sector, as it represents an advancement in making sophisticated cardiac diagnostics more accessible and portable. The latest news and updates relating to the company are available in its newsroom at https://ibn.fm/BEAT.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp
. The source URL for this press release is HeartBeam Receives Buy Rating Upgrade Following FDA Clearance for Cardiac Technology.
The post HeartBeam Receives Buy Rating Upgrade Following FDA Clearance for Cardiac Technology appeared first on citybuzz.
You May Also Like
FCA, crackdown on crypto
Mockery Is Chelsea And Liam Rosenior’s Biggest Enemy
